There's never a shortage of losers in the stock market. Let's take a closer look at five of this past week's biggest sinkers.


March 28

Weekly Loss

Exelixis (NASDAQ:EXEL)






Rally Software (NYSE:RALY)



Kandi Technologies (NASDAQ:KNDI)






Source: Barron's.

Let's start with Exelixis. The biotech shed nearly half of its value after a critical study of its cabozantinib in treating metastatic castration-resistant prostate cancer fell short of expectations. A more diversified biotech could withstand a hit like this, but a lot of the value in Exelixis was based on the the efficacy of this single drug.

MannKind investors and needle-weary diabetes sufferers are hoping that an inhaled insulin can improve their situations. However, an FDA staff review is raising concerns about MannKind's Afrezza. The treatment's impact on lung function is just one of the many concerns that may hold Afrezza back, and investors decided to take one not-so-small step back on MannKind.

Rally Software continued to sell off after posting disappointing quarterly results a week earlier. The provider of cloud-based solutions for managing Agile software development may have posted a narrower deficit than analysts were targeting, but its guidance was uninspiring. 

Kandi slumped after Jim Cramer passed on the opportunity to offer a bullish perspective. The stock came up during Mad Money's Lightning Round on Monday, but Cramer countered that he preferred a larger stateside maker of off-road vehicles. Naturally Kandi bulls will argue that the comments miss the mark. Kandi's appeal has been in the electric cars that it's now working on and growing participation in Chinese auto-sharing offerings.   

Organovo stumbled despite presenting at the 2nd Annual Regen Med Investor Day on Wednesday. Organovo has a great story to tell. It's toiling away on 3-D proxies of human tissues that could be used for medical research and therapeutic applications. The stock's been volatile, and even after this past week's sell-off it has still nearly tripled since the start of last year.

Ready for a bounce
If you owned some of these losers, how about following the smart money into winners? Consider that David Gardner has proved the critics wrong time, and time, and time again with stock returns like 926%, 2,239%, and 4,371%. In fact, just recently one of his favorite stocks became a 100-bagger. And he's ready to do it again. You can uncover his scientific approach to crushing the market and his carefully chosen six picks for ultimate growth instantly, because he's making this premium report free for you today. Click here now for access.

Rick Munarriz owns shares of MannKind. The Motley Fool recommends and owns shares of Exelixis. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Compare Brokers